Chief Financial Officer · Bicara Therapeutics Inc. · Bicara Therapeutics Inc. — Stock Option (Right to Buy)
Side
M
Value
—
Shares
9,200
Price
—
Executed
Dec 22, 2025
Disclosed
Dec 23, 2025
Disclosure timeline1 days from execution to publication · legal deadline 2 business days
Dec 22 executedDec 23, 2025 disclosed
BCAX · daily
Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Option exercise — administrative, little informational value
Relative size+5 / 25
No reported dollar value · 11.5% of prior position
Filing timing0 / 15
Disclosed 1 business day after execution (deadline: 2)
Historical behavior+4 / 15
2 prior trades recorded in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
Pre-arranged plan-10
Executed under a Rule 10b5-1 trading plan
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Bicara Therapeutics Inc. — Stock Option (Right to Buy)
Ticker
BCAX
Shares
9,200
Price per share
$0
Execution date (reported)
Dec 22, 2025
Owned after transaction
89.0K shares
Rule 10b5-1 plan
Yes, as checked by the filer
Days from execution to publication
1
What this establishes
Hyep Ivan filed this Form 4 reporting a option exercise of BCAX on Dec 22, 2025. It became public on Dec 23, 2025. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Chief Financial Officer
Hyep Ivancik:0002034668
Issuer
Bicara Therapeutics Inc.cik:0002023658
Revision history · 0
No field has changed since this record was first ingested.
